Rivaroxaban Compares Favorably with Enoxaparin in Preventing Venous Thromboembolism in Acutely Ill Patients Without Showing a Net Clinical Benefit

Pas encore traduit Pas encore traduit
Auteurs
Catégorie Primary study
SignalerWashington, DC: American College of Cardiology
Year 2011
MAGELLAN Study Shows Strong Efficacy Outcomes but Weaker Safety Outcomes for use of Rivaroxaban in Acutely Ill Hospitalized Patients
Epistemonikos ID: 3b4428277c3cc1082ca62e67f36c24b70cbef9bc
First added on: Apr 24, 2014